ABSTRACT
Objective The COVID-19 pandemic generated a massive amount of clinical data, which potentially holds yet undiscovered answers related to COVID-19 morbidity, mortality, long term effects, and therapeutic solutions. The objective of this study was to generate insights on COVID-19 mortality-associated factors and identify potential new therapeutic options for COVID-19 patients by employing artificial intelligence analytics on real-world data.
Methods A Bayesian statistics-based artificial intelligence data analytics tool (bAIcis®) within Interrogative Biology® platform was used for network learning, inference causality and hypothesis generation to analyze 16,277 PCR positive patients from a database of 279,281 inpatients and outpatients tested for SARS-CoV-2 infection by antigen, antibody, or PCR methods during the first pandemic year in Central Florida. This approach generated causal networks that enabled unbiased identification of significant predictors of mortality for specific COVID-19 patient populations. These findings were validated by logistic regression, regression by least absolute shrinkage and selection operator, and bootstrapping.
Results We found that in the SARS-CoV-2 PCR positive patient cohort, early use of the antiemetic agent ondansetron was associated with increased survival in mechanically ventilated patients.
Conclusions The results demonstrate how real world COVID-19 focused data analysis using artificial intelligence can generate valid insights that could possibly support clinical decision-making and minimize the future loss of lives and resources.
Competing Interest Statement
The authors declare: GMM, RS, LOR, CB, NMC, KR, MAK, and NRN are employees of BERG, LLC and received support from BERG, LLC for the submitted work. GMM, RS, LOR, NMC, KR, MAK, EG, and NRN have stock or stock options in BERG, LLC. GMM has received support for attending meetings and/or travel from BERG, LLC and patents planned, issued, or pending by BERG, LLC. LOR has other financial or non-financial interest in BERG, LLC. EG has leadership or fiduciary role on the Cigna board, BERG, LLC board, Cerner Electronic Medical Record, and Defense Logistics Health board. EG has stock or stock options in BERG, LLC, Cerner, and Defense Logistics Health, and Cigna. NRN is a co-founder of BERG, LLC. No other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
This research used resources of the Oak Ridge Leadership Computing Facility at the Oak Ridge National Laboratory, which is supported by the Office of Science of the U.S. Department of Energy under Contract No. DE-AC05-00OR22725. Research support also provided by the AdventHealth Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
AdventHealth IRB https://www.adventhealthresearchinstitute.com/research/institutional-review-board
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Concept and manuscript review (GM, DL, RS, NN, AP, JS), wrote the manuscript (GM, DL, CB, RS), network generation (AE, JH), data analysis (CB, GM, LR, JH, DL), data architecture, annotation, cleaning (RV, CH, JH), manuscript review (EG, SRS, BG). All authors read and approved the final manuscript.
Data Availability
De-identified data is available per request to the corresponding author
